drugset / Trial / NCT03602638
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
RandomizedParallel-groupSingle-blindTreatment
Summary
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
Timeline
- Start
- 2018-10-01
- Primary completion
- 2019-05-01
- Completion
- 2020-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acarbose | Unknown | — | — |
| Subject | Sitagliptin | Small molecule | 100 mg | — |